BioSpace News Archive

Feb. 19, 2020 13:00 UTC BERKELEY, Calif. & RICHMOND, Calif.--( BUSINESS WIRE )-- Caribou Biosciences, Inc., a leading CRISPR genome editing company, and ProMab Biotechnologies, Inc., a biotechnology CRO/CDMO specializing in antibody engineering and CAR-T development, today announced a sale and assignment agreement under which Caribou gains access to a ProMab humanized single-chain variable fragment (scFv) targeting the B Cell Maturation Antigen (BCMA) for use in allogeneic eng

Myomo, Inc. announced that it has signed an agreement with HOMELINK which will enable Myomo to process out-of-network claims for its MyoPro powered orthosis with the 1,200 payers in HOMELINK’s network.

Feb. 19, 2020 13:00 UTC CHARLOTTE, N.C.--( BUSINESS WIRE )-- Premier Inc . (NASDAQ: PINC), through its ProvideGx ™ program, has partnered with Pfizer Inc. to supply Corvert® (ibutilide fumarate injection) and Vincristine Sulfate Injection, USP, to healthcare providers, to help stabilize the long-term supply of two vital medications for its members. Corvert is an anti-arrhythmic heart medication used to treat atrial fibrillation or atrial flutter. Vincristine is a chemothera

Feb. 19, 2020 13:00 UTC ESCAPE Bio to Present at the 9 th Annual SVB Leerink Global Healthcare Conference SAN FRANCISCO--( BUSINESS WIRE )-- ESCAPE Bio, Inc. , a clinical stage company developing novel, precisely targeted therapeutics for genetically defined neurodegenerative diseases, today announced that Julie Anne Smith, Chief Executive Officer, will present at the 9th Annual SVB Leerink Global Healthcare Conference on Tuesday, February 25, 2020. Presentation details

The CIBMTR® announced the selection of IQVIA as it seeks to expand the value real world data can bring to patients, through systematic investigation to generate real world evidence.

Feb. 19, 2020 13:00 UTC Industry veteran to helm newly created position as H3 advances oncology pipeline CAMBRIDGE, Mass.--( BUSINESS WIRE )-- H3 Biomedicine, Inc. (H3), a U.S.-based precision medicine research & development subsidiary of Eisai Co., Ltd., today announced the appointment of Antonio Gualberto, MD, PhD, to the position of Chief Medical Officer (CMO). Dr. Gualberto will oversee global clinical research & development for the H3 pipeline of clinical sta

Feb. 19, 2020 13:00 UTC Partnership augments caresyntax’s digital ecosystem in surgery, accelerates solution delivery and increases integration capacity. BOSTON--( BUSINESS WIRE )-- caresyntax, a pioneer in surgical automation, quality analytics and AI software and technologies, today announced the launch of a new partnership with Diversified, an industry leading technology solutions integrator. The partnership will enable caresyntax to accelerate the development and deploy

BERKELEY, Calif., Feb. 19, 2020 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ: ADRO) today announced that Stephen T. Isaacs, chairman, president and chief executive officer of Aduro, is scheduled to present at the 9 th Annual SVB Leerink Global Healthcare Conference in New York, New York on Wednesday, February 26, 2020 at 9:00 am ET. To access the live webcast and subsequent archived recording of this and other company presentations, please visit the investor section of Aduro’s website at

AUSTIN, Texas, Feb. 19, 2020 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) (“XBiotech”) today announced the final results of its “modified Dutch auction” tender offer, which expired at 5:00 p.m., New York City time, on February 12, 2020. Based on the final count by American Stock Transfer & Trust Co., LLC, the depositary for the tender offer, a total of 40,007,286 common shares, no par value, were properly tendered and not properly withdrawn at or below the maximum purchase price of $

DUBLIN, IRELAND, Feb. 19, 2020 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced that it will participate in the Raymond James Institutional Investor Conference on Monday, March 2, 2020. Michael J. Tokich, STERIS’s Senior Vice President and Chief Financial Officer will present at 7:30 a.m. Eastern Time. A simultaneous webcast and replay of the Company’s presentation will be available on STERIS’s investor relations website at www.steris-ir.com. About STERI